Korro secures approvals in Australia to commence AATD trial of KRRO-110
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110,…
Genetic Disorders
-
-
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy
Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial…
-
Wave’s stock swells as it eyes approval following Phase II DMD victory
Wave Life Sciences is eyeing an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, with the company’s stock price…
-
Pipeline Moves: Investigator-led oncology cell therapy trial terminated
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
-
Satellos to commence Phase I trial for DMD drug
Canada-based Satellos Bioscience will be dosing the first patient in a Phase I trial of its Duchenne muscular dystrophy (DMD)…
-
YolTech doses first subject in Phase I trial for YOLT-201 therapy
China-based YolTech Therapeutics has dosed the first patient as part of its Phase I clinical trial for gene editing therapy…
-
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease
Spur Therapeutics has announced that its gene therapy candidate for Gaucher disease will soon be moving to a Phase III…
-
CSL Behring treats two patients with gene therapy for haemophilia B
CSL Behring has announced the treatment of two patients with HEMGENIX (etranacogene dezaparvovec) gene therapy for haemophilia B, an inherited…
-
Unravel Biosciences enters partnership to trial Pitt Hopkins Syndrome treatment
US-based therapeutics company Unravel Biosciences has partnered with the Pitt Hopkins Research Foundation to carry out a proof-of-concept trial of…
-
Elpida Therapeutics to start Phase III gene therapy trial for SGP50
A man who set up a rare disease biotech in a bid to cure his son’s disease will soon be…
